Elevance Health (NYSE:ELV) Sets New 52-Week High After Dividend Announcement

Elevance Health, Inc. (NYSE:ELV)’s share price reached a new 52-week high during mid-day trading on Tuesday following a dividend announcement from the company. The company traded as high as $437.00 and last traded at $434.2820, with a volume of 39,762 shares. The stock had previously closed at $430.23.

The newly announced dividend which will be paid on Friday, December 18th. Shareholders of record on Friday, December 4th will be paid a dividend of $1.72 per share. This represents a $6.88 annualized dividend and a yield of 1.6%. The ex-dividend date of this dividend is Friday, December 4th. Elevance Health’s payout ratio is 30.58%.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on ELV shares. The Goldman Sachs Group reiterated a “neutral” rating and issued a $395.00 target price on shares of Elevance Health in a report on Thursday, July 16th. TD Cowen raised their price target on shares of Elevance Health from $400.00 to $465.00 and gave the stock a “buy” rating in a report on Tuesday, July 14th. Wells Fargo & Company decreased their price target on shares of Elevance Health from $492.00 to $473.00 and set an “overweight” rating for the company in a report on Thursday, July 16th. Sanford C. Bernstein set a $488.00 price objective on shares of Elevance Health in a research report on Thursday, July 16th. Finally, Guggenheim upped their price objective on shares of Elevance Health from $455.00 to $460.00 and gave the company a “buy” rating in a research note on Monday, October 12th. Fifteen research analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $441.71.

Elevance Health Trading Down 1.1%

The firm has a market capitalization of $94.39 billion, a PE ratio of 19.34, a price-to-earnings-growth ratio of 2.29 and a beta of 0.70. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.52 and a quick ratio of 1.52. The company has a fifty day moving average of $406.59 and a 200-day moving average of $389.52.

Elevance Health (NYSE:ELV) last issued its earnings results on Wednesday, October 21st. The company reported $6.99 EPS for the quarter, beating analysts’ consensus estimates of $4.71 by $2.28. Elevance Health had a return on equity of 14.64% and a net margin of 2.47%. The firm had revenue of $50.44 billion for the quarter, compared to the consensus estimate of $49.28 billion. During the same quarter in the previous year, the company posted $6.03 earnings per share. The business’s quarterly revenue was up .7% compared to the same quarter last year. On average, sell-side analysts anticipate that Elevance Health, Inc. will post 27.20 earnings per share for the current fiscal year.

More Elevance Health News

Here are the key news stories impacting Elevance Health this week:

• Positive Sentiment: Quarterly results exceeded expectations: Adjusted earnings were $6.99 per share versus the roughly $4.66–$4.71 consensus estimate, while revenue reached $50.44 billion, above expectations of about $49.22 billion. Earnings also increased from $6.03 per share a year earlier. Elevance Health Reports Third Quarter 2026 Results; Raises Full-Year Guidance
• Positive Sentiment: 2026 outlook was raised: Management lifted its underlying earnings baseline to at least $26.75 per share, citing disciplined expense management and better medical-cost performance. Elevance also expects at least 12% adjusted EPS growth in 2027 from the higher earnings base. Elevance lifts 2026 profit forecast on better medical cost management
• Positive Sentiment: Carelon remained a growth driver: Strength in the services business helped offset pressure elsewhere, supporting management’s confidence in future growth. Elevance named Jeff Park president of Carelon, effective December 1, to lead its next expansion phase. Elevance Health Names Jeff Park President of Carelon
• Neutral Sentiment: Elevance declared a quarterly dividend of $1.72 per share, or $6.88 annualized, representing a yield of approximately 1.6%. The payout supports shareholder returns but is unlikely to be the primary near-term trading catalyst.
• Negative Sentiment: Membership pressure remains a concern: The earnings beat occurred despite declining medical membership, increasing investor focus on enrollment trends and the company’s ability to sustain growth.
• Negative Sentiment: Although cost management improved, Elevance operates on a thin net margin, and continued medical-cost inflation or weaker enrollment could limit the benefit of the raised forecast. The shares have also recently traded near a 52-week high, potentially increasing profit-taking risk.

Hedge Funds Weigh In On Elevance Health

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ELV. Pinnacle Bancorp Inc. grew its position in Elevance Health by 26.2% in the third quarter. Pinnacle Bancorp Inc. now owns 164 shares of the company’s stock worth $64,000 after acquiring an additional 34 shares in the last quarter. Vest Financial LLC increased its stake in shares of Elevance Health by 7.5% during the 3rd quarter. Vest Financial LLC now owns 60,888 shares of the company’s stock worth $23,674,000 after purchasing an additional 4,261 shares during the last quarter. Cantor Fitzgerald Investment Advisors L.P. raised its holdings in shares of Elevance Health by 1.8% during the 3rd quarter. Cantor Fitzgerald Investment Advisors L.P. now owns 4,030 shares of the company’s stock valued at $1,567,000 after purchasing an additional 70 shares in the last quarter. Canoe Financial LP raised its holdings in shares of Elevance Health by 0.3% during the 3rd quarter. Canoe Financial LP now owns 364,526 shares of the company’s stock valued at $139,129,000 after purchasing an additional 1,022 shares in the last quarter. Finally, 365 WMG Private Fund I Primus Fund LLC bought a new position in shares of Elevance Health during the 3rd quarter valued at $930,000. Institutional investors own 89.24% of the company’s stock.

Elevance Health Company Profile

Elevance Health, Inc (NYSE: ELV) is a diversified health benefits company that provides health insurance and related services in the United States. Its offerings serve employers, individuals and families, as well as members of government-sponsored programs, including Medicare and Medicaid. The company provides medical, pharmacy, behavioral health and other benefits through a range of health plans and specialty products.

Elevance Health operates its health benefits businesses through a portfolio that includes Blue Cross and Blue Shield-affiliated plans and other insurance offerings.